Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety extension of miransertib in PROS and Proteus syndrome
2021-001369-19Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of miransertib in PIK3CA-related overgrowth spectrum (PROS) and Proteus syndrome (PS), sponsored by Merck & Co. Primary endpoint: Serious adverse events. Started Oct 2021; status: active.
02
Drugs
miransertib
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)Proteus syndrome (PS)
Beyond the preview
Go deeper on 2021-001369-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001369-19.